日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Dextromethorphan Enhances Apoptosis and Suppresses EMT in PANC-1 Pancreatic Cancer Cells: Synergistic Effects with Gemcitabine

右美沙芬增强PANC-1胰腺癌细胞凋亡并抑制EMT：与吉西他滨具有协同作用

期刊:International Journal of Molecular Sciences
影响因子:4.9
doi:10.3390/ijms26178151
Medet, Gulsah; Inal, Ahmet
肿瘤
凋亡
表观遗传
肿瘤免疫
细胞生物学
Apoptosis
胰腺癌
发表日期：2025
文献求助 收藏

Bioequivalence and Pharmacokinetics of Low-Dose Anagrelide 0.5 mg Capsules in Healthy Volunteers

低剂量阿那格雷0.5毫克胶囊在健康志愿者中的生物等效性和药代动力学

期刊:Biomedicines
影响因子:3.9
doi:10.3390/biomedicines13081993
Inal, Ahmet; Sezer, Zafer; Pinarbasli, Onur; Bulut, Burcu; Reinsch, Martin; Martin, Wolfgang; Mazicioglu, Mumtaz M; Koru, Selma Alime
发表日期：2025
文献求助 收藏

Vaccination with inactivated SARS-CoV-2 vaccine TURKOVAC induces durable humoral and cellular immune responses up to 8 months.

接种灭活 SARS-CoV-2 疫苗 TURKOVAC 可诱导长达 8 个月的持久体液和细胞免疫反应

期刊:Frontiers in Medicine
影响因子:3
doi:10.3389/fmed.2025.1524393
Yılmaz Seçil, Eken Ahmet, Sezer Zafer, Bağcı Burcu Şen, Erdem Serife, Sarıkaya Medine Doğan, Kaplan Busra, Inal Ahmet, Bayram Adnan, Kalın Unuvar Gamze, Zararsız Gokmen, Yerlitas Serra İlayda, Cakir Nuri, Pavel Shaikh Terkis Islam, Uygut Muhammet Ali, Yetiskin Hazel, Kara Ates, Ozdarendeli Aykut
细胞生物学
新冠
发表日期：2025
文献求助 收藏

Long-Term Immunogenicity and Safety of a Homologous Third Dose Booster Vaccination with TURKOVAC: Phase 2 Clinical Study Findings with 32-Week Post-Booster Follow-Up

TURKOVAC同源第三剂加强免疫疫苗的长期免疫原性和安全性：2期临床研究结果及加强免疫后32周随访

期刊:Vaccines
影响因子:3.4
doi:10.3390/vaccines12020140
Sezer, Zafer; Pavel, Shaikh Terkis Islam; Inal, Ahmet; Yetiskin, Hazel; Kaplan, Busra; Uygut, Muhammet Ali; Aslan, Ahmet Furkan; Bayram, Adnan; Mazicioglu, Mumtaz; Kalin Unuvar, Gamze; Yuce, Zeynep Ture; Aydin, Gunsu; Kaya, Refika Kamuran; Ates, Ihsan; Kara, Ates; Ozdarendeli, Aykut
免疫/内分泌
发表日期：2024
文献求助 收藏

Bioequivalence study of low dose drospirenone/ethinyl estradiol 3 mg/0.03 mg film tablets under fasting conditions in Turkish healthy female subjects

在土耳其健康女性受试者中，空腹条件下低剂量屈螺酮/炔雌醇 3 mg/0.03 mg 薄膜片的生物等效性研究

期刊:Pharmacology Research & Perspectives
影响因子:2.3
doi:10.1002/prp2.1253
Inal, Ahmet; Sezer, Zafer; Uluözlü, Berna; Oflas, Melih; Reinsch, Martin; Martin, Wolfgang; Mazicioglu, Mümtaz M; Koru, Selma Alime
发表日期：2024
文献求助 收藏

Bioequivalence study of eltrombopag 75 mg film-coated tablets under fasting conditions during the Covid-19 pandemic in healthy Caucasian male subjects

在新冠肺炎疫情期间，对健康白种男性受试者进行空腹条件下艾曲波帕75毫克薄膜衣片的生物等效性研究

期刊:
影响因子:
doi:10.1186/s40360-024-00803-0
Inal, Ahmet; Sezer, Zafer; Pinarbasli, Onur; Bulut, Burcu; Reinsch, Martin; Martin, Wolfgang; Mazicioglu, Mumtaz M; Koru, Selma Alime
肺炎
新冠
微生物学
发表日期：2024
文献求助 收藏

Safety and Efficacy of a Novel Combination Cream (GN-037) in Healthy Volunteers and Patients with Plaque Psoriasis: A Phase 1 Trial

新型复方乳膏（GN-037）在健康志愿者和斑块状银屑病患者中的安全性和有效性：一项1期试验

期刊:Dermatology and Therapy
影响因子:4.2
doi:10.1007/s13555-023-00939-7
Sezer, Zafer; Inal, Ahmet; Cinar, Salih L; Mazicioglu, Mustafa M; Altug, Sedat; Karasulu, Hatice Y; Diril, Mine; Mehmetoglu Al, Ayca; Kozlu, Serhat; Ulu, Nadir
银屑病
发表日期：2023
文献求助 收藏

Safety and immunogenicity of an inactivated whole virion SARS-CoV-2 vaccine, TURKOVAC, in healthy adults: Interim results from randomised, double-blind, placebo-controlled phase 1 and 2 trials

灭活全病毒SARS-CoV-2疫苗TURKOVAC在健康成人中的安全性和免疫原性：随机、双盲、安慰剂对照的1期和2期试验的中期结果

期刊:
影响因子:
doi:10.1016/j.vaccine.2022.10.093
Ozdarendeli, Aykut; Sezer, Zafer; Pavel, Shaikh Terkis Islam; Inal, Ahmet; Yetiskin, Hazel; Kaplan, Busra; Uygut, Muhammet Ali; Bayram, Adnan; Mazicioglu, Mumtaz; Unuvar, Gamze Kalin; Yuce, Zeynep Ture; Aydin, Gunsu; Aslan, Ahmet Furkan; Kaya, Refika Kamuran; Koc, Rabia Cakir; Ates, Ihsan; Kara, Ates
微生物学
SARS-CoV-2
免疫/内分泌
发表日期：2023
文献求助 收藏